Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions, hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA) with BL8040

"BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions Efficacy and safety study, in collaboration with MD Anderson Cancer Center, will assess BL-8040 as combination treatment with immunosuppressants Interim results of study, in patients with hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA), expected by end of 2016"

Go to Top